
BBNX Stock Forecast & Price Target
BBNX Analyst Ratings
Bulls say
Beta Bionics Inc. demonstrated strong financial performance in Q3'25, reporting revenue of $27.3 million, reflecting a substantial year-over-year growth of 63.3%, exceeding estimates by $3.8 million. The company has also raised its fiscal year 2025 revenue guidance to exceed $96.5 million, suggesting positive momentum in sales driven by new patient starts and an increasing portion of revenue coming from the pharmacy channel, which generates significantly higher margins. Furthermore, the upward revisions in revenue estimates for 2025 and 2026, now projected at $97.5 million and $136 million respectively, underscore a robust outlook for top-line growth in the coming years, supported by successful expansion efforts and a rising market share in the insulin pump sector.
Bears say
Beta Bionics faces significant risks that could negatively impact its financial outlook, including challenges in gaining market share for its iLet product amidst competitive pressures and difficulties in establishing pharmacy channel penetration, which may lead to downward revisions in revenue and profitability estimates. The company is also contending with potential delays in clinical development and the lack of FDA marketing approval for Type 2 diabetes, diminishing its competitive edge compared to peers. Additionally, a projected EBITDA loss of $12.2 million, which exceeded previous estimates, combined with the need for additional capital that might lead to shareholder dilution, further complicates Beta Bionics's financial situation moving forward.
This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.
BBNX Analyst Forecast & Price Prediction
Start investing in BBNX
Order type
Buy in
Order amount
Est. shares
0 shares